<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39337495</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura-Differences Compared to COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10007</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251810007</ELocationID><Abstract><AbstractText>Thromboinflammation/immunothrombosis plays a role in several diseases including thrombotic thrombocytopenic purpura (TTP) and COVID-19. Unlike the extensive research that has been conducted on COVID-19 cytokine storms, the baseline and acute phase cytokine profiles of TTP are poorly characterized. Moreover, we compared the cytokine profiles of TTP and COVID-19 to identify the disease-specific/general characteristics of thromboinflammation/immunothrombosis. Plasma concentrations of 33 soluble mediators (SMs: cytokines, chemokines, soluble receptors, and growth factors) were measured by multiplex bead-based LEGENDplex™ immunoassay from 32 COVID-19 patients (32 non-vaccinated patients in three severity groups), 32 TTP patients (remission/acute phase pairs of 16 patients), and 15 control samples. Mainly, the levels of innate immunity-related SMs changed in both diseases. In TTP, ten SMs decreased in both remission and acute phases compared to the control, one decreased, and two increased only in the acute phase compared to remission, indicating mostly anti-inflammatory changes. In COVID-19, ten pro-inflammatory SMs increased, whereas one decreased with increasing severity compared to the control. In severe COVID-19, sixteen SMs exceeded acute TTP levels, with only one higher in TTP. PCA identified CXCL10, IL-1RA, and VEGF as the main discriminators among their cytokine profiles. The innate immune response is altered in both diseases. The cytokine profile of TTP suggests a distinct pathomechanism from COVID-19 and supports referring to TTP as thromboinflammatory rather than immunothrombotic, emphasizing thrombosis over inflammation as the driving force of the acute phase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demeter</LastName><ForeName>Flóra</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0149-2871</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bihari</LastName><ForeName>György</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vadicsku</LastName><ForeName>Dorina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinkovits</LastName><ForeName>György</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5355-7318</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kajdácsi</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Group for Immunology and Hematology, Semmelweis University-HUN-REN-SU (Office for Supported Research Groups), 1085 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horváth</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Réti</LastName><ForeName>Marienn</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4682-5628</Identifier><AffiliationInfo><Affiliation>Department of Haematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-1398-3187</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, Semmelweis University, 1083 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iványi</LastName><ForeName>Zsolt</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Therapy, Semmelweis University, 1085 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gál</LastName><ForeName>János</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Therapy, Semmelweis University, 1085 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gopcsa</LastName><ForeName>László</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Haematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reményi</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Haematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szathmáry</LastName><ForeName>Beáta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectology, Central Hospital of Southern Pest, National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakatos</LastName><ForeName>Botond</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectology, Central Hospital of Southern Pest, National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szlávik</LastName><ForeName>János</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectology, Central Hospital of Southern Pest, National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobek</LastName><ForeName>Ilona</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2187-4666</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Therapy, Central Hospital of Southern Pest, National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prohászka</LastName><ForeName>Zita Z</ForeName><Initials>ZZ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Förhécz</LastName><ForeName>Zsolt</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masszi</LastName><ForeName>Tamás</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vályi-Nagy</LastName><ForeName>István</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Haematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Haematology and Infectious Diseases, 1097 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prohászka</LastName><ForeName>Zoltán</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Group for Immunology and Hematology, Semmelweis University-HUN-REN-SU (Office for Supported Research Groups), 1085 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervenak</LastName><ForeName>László</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, 1088 Budapest, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TKP2021-EGA-24 (MOLORKIV)</GrantID><Agency>Ministry of Innovation and Technology of Hungary, European Union</Agency><Country /></Grant><Grant><GrantID>TKP2021-EGA-08</GrantID><Agency>National Research, Development, and Innovation Fund of Hungary</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011697" MajorTopicYN="Y">Purpura, Thrombotic Thrombocytopenic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">immunothrombosis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</Keyword><Keyword MajorTopicYN="N">thromboinflammation</Keyword><Keyword MajorTopicYN="N">thrombotic thrombocytopenic purpura</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337495</ArticleId><ArticleId IdType="pmc">PMC11432022</ArticleId><ArticleId IdType="doi">10.3390/ijms251810007</ArticleId><ArticleId IdType="pii">ijms251810007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Delvaeye M., Conway E.M. Coagulation and innate immune responses: Can we view them separately? Blood. 2009;114:2367–2374. doi: 10.1182/blood-2009-05-199208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-05-199208</ArticleId><ArticleId IdType="pubmed">19584396</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 2013;13:34–45. doi: 10.1038/nri3345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3345</ArticleId><ArticleId IdType="pubmed">23222502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball A.S., Obi A.T., Diaz J.A., Henke P.K. The Emerging Role of NETs in Venous Thrombosis and Immunothrombosis. Front. Immunol. 2016;7:236. doi: 10.3389/fimmu.2016.00236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00236</ArticleId><ArticleId IdType="pmc">PMC4921471</ArticleId><ArticleId IdType="pubmed">27446071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado M.J., López-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., Hughes G.R., Velasco F. Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997;40:834–841. doi: 10.1002/art.1780400509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400509</ArticleId><ArticleId IdType="pubmed">9153543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer A.T., Gorzelanny C., Gebhardt C., Pantel K., Schneider S.W. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treat. Rev. 2022;102:102322. doi: 10.1016/j.ctrv.2021.102322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2021.102322</ArticleId><ArticleId IdType="pubmed">34922151</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrottmaier W.C., Assinger A. The Concept of Thromboinflammation. Hamostaseologie. 2024;44:21–30. doi: 10.1055/a-2178-6491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-2178-6491</ArticleId><ArticleId IdType="pubmed">38417802</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondovic G., Djordjevic D., Udovicic I., Stanojevic I., Zeba S., Abazovic T., Vojvodic D., Abazovic D., Khan W., Surbatovic M. From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19? Biomedicines. 2022;10:2620. doi: 10.3390/biomedicines10102620.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10102620</ArticleId><ArticleId IdType="pmc">PMC9599155</ArticleId><ArticleId IdType="pubmed">36289881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtari T., Hassani F., Ghaffari N., Ebrahimi B., Yarahmadi A., Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J. Mol. Histol. 2020;51:613–628. doi: 10.1007/s10735-020-09915-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10735-020-09915-3</ArticleId><ArticleId IdType="pmc">PMC7533045</ArticleId><ArticleId IdType="pubmed">33011887</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurler L., Szilágyi Á., Mescia F., Bergamaschi L., Mező B., Sinkovits G., Réti M., Müller V., Iványi Z., Gál J., et al. Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups. Front. Immunol. 2023;14:1162171. doi: 10.3389/fimmu.2023.1162171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1162171</ArticleId><ArticleId IdType="pmc">PMC10084477</ArticleId><ArticleId IdType="pubmed">37051252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinkovits G., Réti M., Müller V., Iványi Z., Gál J., Gopcsa L., Reményi P., Szathmáry B., Lakatos B., Szlávik J., et al. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality. Thromb. Haemost. 2022;122:240–256. doi: 10.1055/s-0041-1740182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1740182</ArticleId><ArticleId IdType="pmc">PMC8820843</ArticleId><ArticleId IdType="pubmed">35062036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobó J., Kocsis A., Farkas B., Demeter F., Cervenak L., Gál P. The Lectin Pathway of the Complement System-Activation, Regulation, Disease Connections and Interplay with Other (Proteolytic) Systems. Int. J. Mol. Sci. 2024;25:1566. doi: 10.3390/ijms25031566.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25031566</ArticleId><ArticleId IdType="pmc">PMC10855846</ArticleId><ArticleId IdType="pubmed">38338844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.S., Lee J.Y., Yang J.W., Lee K.H., Effenberger M., Szpirt W., Kronbichler A., Shin J.I. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11:316–329. doi: 10.7150/thno.49713.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.49713</ArticleId><ArticleId IdType="pmc">PMC7681075</ArticleId><ArticleId IdType="pubmed">33391477</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone G., Scacciavillani R., Del Buono M.G., Camilli M., Ronco C., Lavie C.J., Abbate A., Crea F., Massetti M., Aspromonte N. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Med. 2020;10:277–287. doi: 10.1159/000509483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000509483</ArticleId><ArticleId IdType="pmc">PMC7360507</ArticleId><ArticleId IdType="pubmed">32599589</ArticleId></ArticleIdList></Reference><Reference><Citation>Borish L.C., Steinke J.W. 2. Cytokines and chemokines. J. Allergy Clin. Immunol. 2003;111:S460–S475. doi: 10.1067/mai.2003.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mai.2003.108</ArticleId><ArticleId IdType="pubmed">12592293</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Chu D., Kalantar-Zadeh K., George J., Young H.A., Liu G. Cytokines: From Clinical Significance to Quantification. Adv. Sci. 2021;8:e2004433. doi: 10.1002/advs.202004433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202004433</ArticleId><ArticleId IdType="pmc">PMC8336501</ArticleId><ArticleId IdType="pubmed">34114369</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.J., Dong X., Liu G.H., Gao Y.D. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin. Rev. Allergy Immunol. 2023;64:90–107. doi: 10.1007/s12016-022-08921-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-022-08921-5</ArticleId><ArticleId IdType="pmc">PMC8767775</ArticleId><ArticleId IdType="pubmed">35044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukumar S., Lämmle B., Cataland S.R. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J. Clin. Med. 2021;10:536. doi: 10.3390/jcm10030536.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10030536</ArticleId><ArticleId IdType="pmc">PMC7867179</ArticleId><ArticleId IdType="pubmed">33540569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasco E., Bütikofer L., Friedman K.D., George J.N., Hrachovinova I., Knöbl P.N., Matsumoto M., von Krogh A.S., Aebi-Huber I., Cermakova Z., et al. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood. 2021;137:3563–3575. doi: 10.1182/blood.2020009801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020009801</ArticleId><ArticleId IdType="pubmed">33649760</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikes B., Sinkovits G., Farkas P., Csuka D., Rázsó K., Réti M., Radványi G., Demeter J., Prohászka Z. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. Thromb. Haemost. 2016;115:1034–1043. doi: 10.1160/th15-07-0564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th15-07-0564</ArticleId><ArticleId IdType="pubmed">26763086</ArticleId></ArticleIdList></Reference><Reference><Citation>Roose E., Schelpe A.S., Tellier E., Sinkovits G., Joly B.S., Dekimpe C., Kaplanski G., Le Besnerais M., Mancini I., Falter T., et al. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood. 2020;136:353–361. doi: 10.1182/blood.2019004221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019004221</ArticleId><ArticleId IdType="pubmed">32356859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinkovits G., Szilágyi Á., Farkas P., Inotai D., Szilvási A., Tordai A., Rázsó K., Réti M., Prohászka Z. Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura. Front. Immunol. 2018;9:1646. doi: 10.3389/fimmu.2018.01646.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01646</ArticleId><ArticleId IdType="pmc">PMC6054987</ArticleId><ArticleId IdType="pubmed">30061898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinkovits G., Prohászka Z. Update on the role of the complement system in the pathogenesis of thrombotic microangiopathies. Pril. (Makedon. Akad. Nauk. Umet. Odd. Med. Nauki) 2014;35:115–122.</Citation><ArticleIdList><ArticleId IdType="pubmed">24802312</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojnar E., Józsi M., Szabó Z., Réti M., Farkas P., Kelen K., Reusz G.S., Szabó A.J., Garam N., Mikes B., et al. Elevated Systemic Pentraxin-3 Is Associated with Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. Front. Immunol. 2019;10:240. doi: 10.3389/fimmu.2019.00240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00240</ArticleId><ArticleId IdType="pmc">PMC6397851</ArticleId><ArticleId IdType="pubmed">30858847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiszel P., Sík P., Miklós J., Kajdácsi E., Sinkovits G., Cervenak L., Prohászka Z. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history. Sci. Rep. 2023;13:13166. doi: 10.1038/s41598-023-40103-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-40103-x</ArticleId><ArticleId IdType="pmc">PMC10423719</ArticleId><ArticleId IdType="pubmed">37574522</ArticleId></ArticleIdList></Reference><Reference><Citation>Shariatmadar S., Nassiri M., Vincek V. Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. Am. J. Hematol. 2005;79:83–88. doi: 10.1002/ajh.20342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.20342</ArticleId><ArticleId IdType="pubmed">15929111</ArticleId></ArticleIdList></Reference><Reference><Citation>Papic N., Samadan L., Vrsaljko N., Radmanic L., Jelicic K., Simicic P., Svoboda P., Lepej S.Z., Vince A. Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease. Life. 2022;12:795. doi: 10.3390/life12060795.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12060795</ArticleId><ArticleId IdType="pmc">PMC9225218</ArticleId><ArticleId IdType="pubmed">35743825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohji G., Funakoshi Y., Ebisawa K., Yakushijin K., Arakawa Y., Saegusa J., Kawamoto S., Imanishi T., Mori Y., Iwata K., et al. Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases. Kobe J. Med. Sci. 2021;67:E55–E60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8622216</ArticleId><ArticleId IdType="pubmed">34795156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Escobar L.G., Hoffman K.L., Choi J.J., Borczuk A., Salvatore S., Alvarez-Mulett S.L., Galvan M.D., Zhao Z., Racine-Brzostek S.E., Yang H.S., et al. Cytokine signatures of end organ injury in COVID-19. Sci. Rep. 2021;11:12606. doi: 10.1038/s41598-021-91859-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91859-z</ArticleId><ArticleId IdType="pmc">PMC8206105</ArticleId><ArticleId IdType="pubmed">34131192</ArticleId></ArticleIdList></Reference><Reference><Citation>Angioni R., Sánchez-Rodríguez R., Munari F., Bertoldi N., Arcidiacono D., Cavinato S., Marturano D., Zaramella A., Realdon S., Cattelan A., et al. Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients. Cell Death Dis. 2020;11:957. doi: 10.1038/s41419-020-03151-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03151-z</ArticleId><ArticleId IdType="pmc">PMC7646225</ArticleId><ArticleId IdType="pubmed">33159040</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., Neves P., Lima S.S., Lopes J.D.C., Torres M., Vallinoto I., Bichara C.D.A., Dos Santos E.F., de Brito M., da Silva A.L.S., et al. Cytokine Profiles Associated with Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell. Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawawi A., Naser A.Y., Alwafi H., Minshawi F. Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis. Front. Immunol. 2021;12:666223. doi: 10.3389/fimmu.2021.666223.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.666223</ArticleId><ArticleId IdType="pmc">PMC8147689</ArticleId><ArticleId IdType="pubmed">34046036</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin R., He L., Yang Z., Jia N., Chen R., Xie J., Fu W., Chen H., Lin X., Huang R., et al. Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: A Systematic Review and Meta-analysis. Clin. Rev. Allergy Immunol. 2023;64:33–65. doi: 10.1007/s12016-021-08908-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08908-8</ArticleId><ArticleId IdType="pmc">PMC8763427</ArticleId><ArticleId IdType="pubmed">35040086</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K., Yang T., Peng X.F., Lv S.M., Ye X.L., Zhao T.S., Li J.C., Shao Z.J., Lu Q.B., Li J.Y., et al. A systematic meta-analysis of immune signatures in patients with COVID-19. Rev. Med. Virol. 2021;31:e2195. doi: 10.1002/rmv.2195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2195</ArticleId><ArticleId IdType="pmc">PMC7744845</ArticleId><ArticleId IdType="pubmed">34260780</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman D.E., Ronner L., Pinotti R., Taylor M.D., Sinha P., Calfee C.S., Hirayama A.V., Mastroiani F., Turtle C.J., Harhay M.O., et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 2020;8:1233–1244. doi: 10.1016/S2213-2600(20)30404-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30404-5</ArticleId><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruytinx P., Vandormael P., Fraussen J., Pieters Z., Thonissen S., Hellings N., Stinissen P., Callebaut I., Penders J., Vanhove K., et al. Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort. Sci. Rep. 2023;13:19322. doi: 10.1038/s41598-023-46421-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-46421-4</ArticleId><ArticleId IdType="pmc">PMC10630327</ArticleId><ArticleId IdType="pubmed">37935729</ArticleId></ArticleIdList></Reference><Reference><Citation>Haljasmägi L., Salumets A., Rumm A.P., Jürgenson M., Krassohhina E., Remm A., Sein H., Kareinen L., Vapalahti O., Sironen T., et al. Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. Sci. Rep. 2020;10:20533. doi: 10.1038/s41598-020-77525-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77525-w</ArticleId><ArticleId IdType="pmc">PMC7689507</ArticleId><ArticleId IdType="pubmed">33239683</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Castejon G., Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011;22:189–195. doi: 10.1016/j.cytogfr.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2011.10.001</ArticleId><ArticleId IdType="pmc">PMC3714593</ArticleId><ArticleId IdType="pubmed">22019906</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.D., Nedjai B., Hurst T., Pennington D.J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta. 2014;1843:2563–2582. doi: 10.1016/j.bbamcr.2014.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2014.05.014</ArticleId><ArticleId IdType="pubmed">24892271</ArticleId></ArticleIdList></Reference><Reference><Citation>Defrance T., Carayon P., Billian G., Guillemot J.C., Minty A., Caput D., Ferrara P. Interleukin 13 is a B cell stimulating factor. J. Exp. Med. 1994;179:135–143. doi: 10.1084/jem.179.1.135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.179.1.135</ArticleId><ArticleId IdType="pmc">PMC2191343</ArticleId><ArticleId IdType="pubmed">7903680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu R., Mao T., Lu Q., Tianjiao Su T., Wang J. Myeloid dysregulation and therapeutic intervention in COVID-19. Semin. Immunol. 2021;55:101524. doi: 10.1016/j.smim.2021.101524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101524</ArticleId><ArticleId IdType="pmc">PMC8576142</ArticleId><ArticleId IdType="pubmed">34823995</ArticleId></ArticleIdList></Reference><Reference><Citation>Almada L., Angiolini S.C., Dho N.D., Dutto J., Gazzoni Y., Manzone-Rodríguez C., Marín C., Ponce N.E., Arroyo D.S., Quiróz J.N., et al. Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities. Front. Immunol. 2023;14:1111797. doi: 10.3389/fimmu.2023.1111797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1111797</ArticleId><ArticleId IdType="pmc">PMC9929547</ArticleId><ArticleId IdType="pubmed">36817433</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergantini L., d’Alessandro M., Cameli P., Otranto A., Luzzi S., Bianchi F., Bargagli E. Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis. Cytokine. 2022;151:155804. doi: 10.1016/j.cyto.2022.155804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2022.155804</ArticleId><ArticleId IdType="pmc">PMC8765080</ArticleId><ArticleId IdType="pubmed">35063722</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirabe A., Heber S., Schrottmaier W.C., Schmuckenschlager A., Treiber S., Pereyra D., Santol J., Pawelka E., Traugott M., Schörgenhofer C., et al. Age Related Differences in Monocyte Subsets and Cytokine Pattern during Acute COVID-19-A Prospective Observational Longitudinal Study. Cells. 2021;10:3373. doi: 10.3390/cells10123373.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123373</ArticleId><ArticleId IdType="pmc">PMC8699549</ArticleId><ArticleId IdType="pubmed">34943881</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Yu B., Yang Y., Huang J., Liang Y., Zhou J., Li L., Peng X., Cheng B., Lin Y. Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. Int. Immunopharmacol. 2021;97:107685. doi: 10.1016/j.intimp.2021.107685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107685</ArticleId><ArticleId IdType="pmc">PMC8052478</ArticleId><ArticleId IdType="pubmed">33951560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesmez Can F., Özkurt Z., Öztürk N., Sezen S. Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection. Int. J. Clin. Pract. 2021;75:e14970. doi: 10.1111/ijcp.14970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14970</ArticleId><ArticleId IdType="pmc">PMC8646602</ArticleId><ArticleId IdType="pubmed">34626520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.G., Simpson L.J., Ferreira A.M., Rustagi A., Roque J., Asuni A., Ranganath T., Grant P.M., Subramanian A., Rosenberg-Hasson Y., et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 2020;5:e140289. doi: 10.1172/jci.insight.140289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140289</ArticleId><ArticleId IdType="pmc">PMC7526438</ArticleId><ArticleId IdType="pubmed">32706339</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetta E., Folci M., Bottazzi B., De Santis M., Gritti G., Protti A., Mapelli S.N., Bonovas S., Piovani D., Leone R., et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 2021;22:19–24. doi: 10.1038/s41590-020-00832-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00832-x</ArticleId><ArticleId IdType="pubmed">33208929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortaz E., Tabarsi P., Jamaati H., Dalil Roofchayee N., Dezfuli N.K., Hashemian S.M., Moniri A., Marjani M., Malekmohammad M., Mansouri D., et al. Increased Serum Levels of Soluble TNF-α Receptor Is Associated with ICU Mortality in COVID-19 Patients. Front. Immunol. 2021;12:592727. doi: 10.3389/fimmu.2021.592727.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.592727</ArticleId><ArticleId IdType="pmc">PMC8100036</ArticleId><ArticleId IdType="pubmed">33968010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman E.R., Cameron C.M.A., Avery A., Gabriel J., Kettelhut A., Hecker M., Sontich C.U., Tamilselvan B., Nichols C.N., Richardson B., et al. Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019. J. Infect. Dis. 2021;223:805–810. doi: 10.1093/infdis/jiaa744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa744</ArticleId><ArticleId IdType="pmc">PMC7799002</ArticleId><ArticleId IdType="pubmed">33249506</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M., Yunis J., Yao Y., Shi J., Yang Y., Zhou P., Liang K., Wan Y., Mehdi A., Chen Z., et al. High levels of soluble CD25 in COVID-19 severity suggest a divergence between anti-viral and pro-inflammatory T-cell responses. Clin. Transl. Immunol. 2021;10:e1251. doi: 10.1002/cti2.1251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1251</ArticleId><ArticleId IdType="pmc">PMC7883478</ArticleId><ArticleId IdType="pubmed">33614032</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwood J.P., Langley K., Heelas E., Machin S.J., Scully M. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br. J. Haematol. 2014;164:858–866. doi: 10.1111/bjh.12707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12707</ArticleId><ArticleId IdType="pmc">PMC4155869</ArticleId><ArticleId IdType="pubmed">24372446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzikonstantinou T., Gavriilaki M., Anagnostopoulos A., Gavriilaki E. An Update in Drug-Induced Thrombotic Microangiopathy. Front. Med. 2020;7:212. doi: 10.3389/fmed.2020.00212.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00212</ArticleId><ArticleId IdType="pmc">PMC7256484</ArticleId><ArticleId IdType="pubmed">32528969</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangié C., Lefaucheur C., Medioni J., Jacquot C., Hill G.S., Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007;8:177–178. doi: 10.1016/S1470-2045(07)70037-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(07)70037-2</ArticleId><ArticleId IdType="pubmed">17267332</ArticleId></ArticleIdList></Reference><Reference><Citation>Yılmaz S., Özçakar Z.B., Taktak A., Kiremitçi S., Ensari A., Dinçaslan H., Yalçınkaya F. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome. Pediatr. Nephrol. 2016;31:1029–1032. doi: 10.1007/s00467-016-3355-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-016-3355-z</ArticleId><ArticleId IdType="pubmed">26928310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapiteijn E., Brand A., Kroep J., Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol. 2007;18:1745–1747. doi: 10.1093/annonc/mdm454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdm454</ArticleId><ArticleId IdType="pubmed">17890216</ArticleId></ArticleIdList></Reference><Reference><Citation>Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., Richardson C., Kopp J.B., Kabir M.G., Backx P.H., et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008;358:1129–1136. doi: 10.1056/NEJMoa0707330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0707330</ArticleId><ArticleId IdType="pmc">PMC3030578</ArticleId><ArticleId IdType="pubmed">18337603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutneja A., Cossey L.N., Liapis H., Chen Y.M. A rare case of renal thrombotic microangiopathy associated with Castleman’s disease. BMC Nephrol. 2017;18:57. doi: 10.1186/s12882-017-0472-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-017-0472-2</ArticleId><ArticleId IdType="pmc">PMC5301347</ArticleId><ArticleId IdType="pubmed">28183278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachary I., Mathur A., Yla-Herttuala S., Martin J. Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2000;20:1512–1520. doi: 10.1161/01.ATV.20.6.1512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.20.6.1512</ArticleId><ArticleId IdType="pubmed">10845866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzierli T., Allegretta F., Maffini E., Allinovi M. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management. Front. Pharmacol. 2022;13:1088031. doi: 10.3389/fphar.2022.1088031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1088031</ArticleId><ArticleId IdType="pmc">PMC9868185</ArticleId><ArticleId IdType="pubmed">36699080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sravanthi M.V., Suma Kumaran S., Sharma N., Bojanapally P. A Rare Case of Acquired Thrombotic Thrombocytopenic Purpura Triggered by Acute Pancreatitis. Cureus. 2020;12:e8477. doi: 10.7759/cureus.8477.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.8477</ArticleId><ArticleId IdType="pmc">PMC7336581</ArticleId><ArticleId IdType="pubmed">32642381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>